Modeling the epidemiological impact and cost-effectiveness of a combined schoolgirl HPV vaccination and cervical cancer screening program among Chinese women

References

• Centers for Disease Control and Prevention. Basic Information about HPV and Cancer. 2018 Aug 22. [accessed 2020 Jun 11]. https://www.cdc.gov/cancer/hpv/basic_info/index.htm.
   Google Scholar
• Senkomago V. Human papillomavirus–attributable cancers—United States, 2012–2016. MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):724–28. doi:10.15585/mmwr.mm6833a3. PMID: 31437140.
   PubMed Web of Science ®Google Scholar
• Laprise C, Trottier H, Monnier P, Coutlée F, Mayrand MH. Prevalence of human papillomaviruses in semen: a systematic review and meta-analysis. Hum Reprod. 2013 Dec 22;29(4):640–51. doi:10.1093/humrep/det453. PMID: 24365799.
   PubMed Web of Science ®Google Scholar
• Ma X, Wang Q, Ong JJ, Fairley CK, Su S, Peng P, Jing J, Wang L, Soe NN, Cheng F, et al. Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis. Sex Transm Infect. 2018 Sep;94(6):434–42. doi:10.1136/sextrans-2017-053412. PMID: 29794242.
   PubMed Web of Science ®Google Scholar
• Gu XY, Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen WQ, He J. Incidence and mortality of cervical cancer in China, 2014. Zhonghua Zhong Liu Za Zhi [Chin J Oncol]. 2018 Apr;40(4):241–46. doi:10.3760/cma.j..0253-3766.2018.04.001. PMID: 297309088.
   PubMedGoogle Scholar
• Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. J Clin Aesthet Dermatol. 2012 Jun;5(6):25–36. PMID: 22768354.
   PubMedGoogle Scholar
• Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal KL, Harper DM, et al. Human papillomavirus and HPV vaccines: a review. World Health Organization. 2007 Sep 1. [accessed 2020 Mar 23]. https://www.who.int/bulletin/volumes/85/9/06-038414/en/.
   Google Scholar
• Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011 Jun 28;105(1):28–37. doi:10.1038/bjc.2011.185. Epub 2011 May 31. PMID: 21629249.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 19;372(8):711–23. doi:10.1056/NEJMoa1405044. PMID: 25693011.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet. 2004 Nov 13–19;364(9447):1757–65. doi:10.1016/S0140-6736(04)17398-4. PMID: 15541448.
   PubMed Web of Science ®Google Scholar
• Gellin B, Modlin JF, Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin Infect Dis. 2007 Sep 1;45(5):609–7. doi:10.1086/520654. PMID: 17682997.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunization, vaccines and biologicals. 2019 Nov 19. [accessed 2018 Oct 18]. http://www.who.int/immunization/global_vaccine_action_plan/en/.
   Google Scholar
• Garland SM, Cornall AM, Brotherton JM, Wark JD, Malloy MJ, Tabrizi SN. VACCINE study group. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine. 2018 May 31;36(23):3221–30. doi:10.1016/j.vaccine.2018.04.080. PMID: 29724506.
   PubMed Web of Science ®Google Scholar
• Chow EP, Read TR, Wigan R, Donovan B, Chen MY, Bradshaw CS, Fairley CK. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015 May;91(3):214–19. doi:10.1136/sextrans-2014-051813. PMID: 25305210.
   PubMed Web of Science ®Google Scholar
• Dyda A, Shah Z, Surian D, Martin P, Coiera E, Dey A, Leask J, Dunn AG. HPV vaccine coverage in Australia and associations with HPV vaccine information exposure among Australian Twitter users. Hum Vaccin Immunother. 2019;15(7–8):1488–95. doi:10.1080/21645515.2019.1596712. PMID: 30978147.
   PubMed Web of Science ®Google Scholar
• Albeck-Ripka L Australia could become first country to eradicate cervical cancer. New York Times. 2018 Oct 3 [accessed 2018 Oct 18]. https://www.nytimes.com/2018/10/03/world/australia/cervical-cancer-hpv-vaccine.html.
   Google Scholar
• Zhang Y, Wang Y, Liu L, Fan Y, Liu Z, Wang Y, Nie S. Awareness and knowledge about human papillomavirus vaccination and its acceptance in China: a meta-analysis of 58 observational studies. BMC Public Health. 2016 Mar 3;16:216. doi:10.1186/s12889-016-2873-8. PMID: 26936076.
   PubMed Web of Science ®Google Scholar
• Zhao FH, Tiggelaar SM, Hu SY, Zhao N, Hong Y, Niyazi M, Gao XH, Ju LR, Zhang LQ, Feng XX, et al. A multi-center survey of HPV knowledge and attitudes toward HPV vaccination among women, government officials, and medical personnel in China. Asian Pac J Cancer Prev. 2012;13(5):2369–78. doi:10.7314/apjcp.2012.13.5.2369. PMID: 22901224.
   PubMedGoogle Scholar
• Wang B, He M, Chao A, Engelgau MM, Saraiya M, Wang L, Wang L. Cervical cancer screening among adult women in China, 2010. Oncologist. 2015 Jun;20(6):627–34. doi:10.1634/theoncologist.2014-0303. PMID: 25956407.
   PubMed Web of Science ®Google Scholar
• Wang SM, Qiao YL. Implementation of cervical cancer screening and prevention in China—challenges and reality. Jpn J Clin Oncol. 2015 Jan;45(1):7–11. doi:10.1093/jjco/hyu188. PMID: 25398583.
   PubMed Web of Science ®Google Scholar
• Bao H, Zhang L, Wang L, Zhang M, Zhao Z, Fang L, Cong S, Zhou M, Wang L. Significant variations in the cervical cancer screening rate in China by individual‐level and geographical measures of socioeconomic status: a multilevel model analysis of a nationally representative survey dataset. Cancer Med. 2018 May;7(5):2089–100. doi:10.1002/cam4.1321. PMID: 29573569.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Qiao YL, Keita N. The next steps in cervical screening. Womens Health (Lond). 2015 Mar;11(2):201–12. doi:10.2217/whe.14.70. PMID: 25776294.
   PubMedGoogle Scholar
• Hestbech MS, Lynge E, Kragstrup J, Siersma V, Baillet MV, Brodersen J. The impact of HPV vaccination on future cervical screening: a simulation study of two birth cohorts in Denmark. BMJ Open. 2015 Aug 14;5(8):e007921. doi:10.1136/bmjopen-2015-007921. PMID: 26275901.
   PubMed Web of Science ®Google Scholar
• Zou Z, Fairley CK, Ong JJ, Hocking J, Canfell K, Ma X, Chow EP, Xu X, Zhang L, Zhuang G. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. The Lancet Global Health. 2020 Oct 1;8(10):e1335–44.
   Google Scholar
• Soe NN, Ong JJ, Ma X, Fairley CK, Latt PM, Jing J, Cheng F, Zhang L. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness. Human vaccines & immunotherapeutics. 2018 Dec 2;14(12):3010–8.
   Google Scholar
• Wang Q, Ma Z, Zhang X, Ong JJ, Jing J, Zhang L, Wang LH. Human papillomavirus infection and associated factors for cervical intraepithelial neoplasia in women living with HIV in China: a cross-sectional study. Sexually transmitted infections. 2019 Mar 1;95(2):140–4.
   Google Scholar
• Fairley CK, Zou H, Zhang L, Chow EP. Human papillomavirus vaccination in men who have sex with men–what will be required by 2020 for the same dramatic changes seen in heterosexuals. Sexual Health. 2017 Feb 1;14(1):123–5.
   Google Scholar
• Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. 2010 Jul 26;28(33);5473–84. doi:10.1016/j.vaccine.2010.05.056. PMID: 20573580.
   Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007 Jan;13(1):28–41. doi:10.3201/eid1301.060438. PMID: 17370513.
   PubMed Web of Science ®Google Scholar
• Mo X, Tobe RG, Wang L, Liu X, Wu B, Luo H, Nagata C, Mori R, Nakayama T. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017 Jul 18;17(1):502. doi:10.1186/s12879-017-2592-5. PMID: 28720082.
   PubMedGoogle Scholar
• Choi HC, Jit M, Leung GM, Tsui KL, Wu JT. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modelling analysis. BMC Med. 2018 Aug 17;16(1):127. doi:10.1186/s12916-018-1118-3. PMID: 30115065.
   PubMedGoogle Scholar
• Song XB, Zhao QJ, Zhou Z, Fang Y. Health economic evaluation of bivalent human papilloma virus vaccine in China: based on the dynamic model. Zhonghua Yu Fang Yi Xue Za Zhi [Chin J Preventive Med]. 2017 Sep 6;51(9):814–20. doi:10.3760/cma.j..0253-9624.2017.09.008. PMID: 28881547.
   PubMedGoogle Scholar
• Zhang Q, Liu YJ, Hu SY, Zhao FH. Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China. BMC Cancer. 2016 Nov 4;16(1):848. doi:10.1186/s12885-016-2893-x. PMID: 27814703.
   PubMedGoogle Scholar
• Cai J, Yang Y. The results analysis of uterine cervical cancer screening in 753310 cases. China Med Herald. 2012;13:134–36.
   Google Scholar
• Cao J, Han H, Li X. Analysis of the prevalence of women’s diseases in Hubei Province from 1998 to 2003. Maternal Child Health Care China. 2005;20:307–08.
   Google Scholar
• Wang L, Zhang Y, Wang C, Han L. Analysis of surveillance status of common sexually transmitted diseases among females in Beijing from 2005 to 2010. Chin J Gen Pract. 2011;25:2923–25.
   Google Scholar
• Geng Q, Sun Z, Lu Y, Wang Q, Li N. Study of the prevalence of RTI/STD and related factors among bearing-age married women in rural areas of Meixian and Huayin of Shaanxi Province. J Xi’an Jiaotong Univ (Med). 2007;28:220–24.
   Google Scholar
• Wu H. Analysis of reproductive tract infections and women’s diseases in 47,538 rural women in Jianshui County. Chin Commun Doctors. 2012;14:300–01.
   Google Scholar
• Wang F. Investigation and analysis of 8,529 cases of reproductive tract infections in married women of childbearing age in rural areas. J Henan Med Coll Staff Workers. 2012;24:34–36.
   Google Scholar
• Expert Committee of China Eugenics Association Colposcopy and Cervical Pathology Branch. Consensus on Cervical cancer screening abnormality regulation. Chin J Clin Obstet Gynecol. 2017 Mar;18(2):190–92. [accessed 2018 Jan 14]. http://www.cdgrlyy.org/common/attached/file/20180614/20180614172446_54232.pdf.
   Google Scholar
• American Cancer Society. Signs and symptoms of cervical cancer. 2020 Jan 3 [accessed 2020 Jul 18]. https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/signs-symptoms.html.
   Google Scholar
• Lv W Cervical Intraepithelial Neoplasias(CIN) Clinical Treatment Guideline (ASCCP). Zhejiang Province gynaecology Annual Conference; 2008; Zhejiang Province. [accessed 2018 Jan 14]. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZJKX200811001007.htm.
   Google Scholar
• Li X, Zheng R, Li X, Shan H, Wu Q, Wang Y, Chen W. Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014. Chin J Cancer Res. 2017 Dec;29(6):477–86. doi:10.21147/j..1000-9604.2017.06.02. PMID: 29353970.
   PubMed Web of Science ®Google Scholar
• Li J, Kang LN, Qiao YL. Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev. 2011 Jan 1;12(5):1149–53. PMID: 21875257.
   PubMedGoogle Scholar
• Wen X, Wen D, Yang Y, Chen Y, Akazawa K, Liu Y, Shan B. Urban-rural disparity in cervical cancer in China and feasible interventions for tackling the rural excess. Medicine (Baltimore). 2019 Jan;98(1):e13907. doi:10.1097/MD.0000000000013907.
   PubMed Web of Science ®Google Scholar
• Census Office. Tabulation of the 2010 population census of the people republic of China. Stat.gov; 2010 [accessed 2018 Dec 3]. http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm.
   Google Scholar
• Yi F, Su J. The fertility wishes and population policy-from the perspective of the practice of two children policy. China Dev Obs. 2018;12:58–74.
   Google Scholar
• Health statistics and information systems. Metrics: disability-Adjusted Life Year (DALY). World Health Organization. [accessed 2018 Oct 18]. http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/.
   Google Scholar
• CEIC Data. China GDP per capita. [accessed 2020 Feb 20]. https://www.ceicdata.com/en/indicator/china/gdp-per-capita.
   Google Scholar
• World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). [accessed 2018 Oct 18]. http://www.who.int/choice/cost-effectiveness/en/.
   Google Scholar
• Investment on breast cancer and cervical cancer screening. Shanghai municipal commission of health and family Planning. [accessed 2018 Oct 18]. http://www.wsjsw.gov.cn/wsj/n429/n432/n1487/n1511/u1ai82600.html.
   Google Scholar
• Watson M, Benard V, Flagg EW. Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003–2014. Prev Med Rep. 2018 Feb 2;9:124–30. doi:10.1016/j.pmedr.2018.01.010. PMID: 29527465.
   PubMedGoogle Scholar
• Jiang Y, Ni W, Wu J. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis. BMJ Open. 2019 Nov 24;9(11):e031186. doi:10.1136/bmjopen-2019-031186. PMID: 31767588.
   PubMed Web of Science ®Google Scholar
• Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, Qiao YL, Jamison DT, Kim JJ, Gelband H, et al. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. Vaccine. 2015 Jun 4;33(24):2830–41. doi:10.1596/978-1-4648-0349-9_ch18. PMID: 26913341.
   PubMed Web of Science ®Google Scholar
• The market size of HPV vaccine is expected to exceed 30 billions. Xinhua Net; 2017 Dec 18 [accessed 2019 Jan 14]. http://www.xinhuanet.com//fortune/2017-12/18/c_1122124456.htm.
   Google Scholar
• Clendinen C, Zhang Y, Warburton RN, Light DW. Manufacturing costs of HPV vaccines for developing countries. Vaccine. 2016 Nov 21;34(48):5984–89. doi:10.1016/j.vaccine.2016.09.042. PMID: 27771183.
   PubMed Web of Science ®Google Scholar
• Fair A Shot for vaccine affordability – understanding and addressing the effects of patents on access to newer vaccines. 2019 Jul [accessed 2019 Jan 14]. https://msfaccess.org/sites/default/files/VAC_report_A%20Fair%20Shot%20for%20Vaccine%20Affordability_ENG_2017.pdf.
   Google Scholar
• China focus: Chinese HPV vaccine to be available in May. Xinhua Net; 2020 Apr 26 [accessed 2020 Jun 11]. http://www.xinhuanet.com/english/2020-04/26/c_139009381.htm.
   Google Scholar
• Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, Chen W, Huang SJ, Zhao FH, Li MQ, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2020 Feb 1;112(2):145–53. doi:10.1093/jnci/djz074. PMID: 31086947.
   PubMedGoogle Scholar
• HPV vaccine market will exceed 100 billions. SINA Finance and Economics; 2018 Jul 28 [accessed 2018 Oct 18]. https://finance.sina.cn/stock/ssgs/2018-07-28/detail-ihfxsxzf7904104.d.html?cre=tianyi&mod=wpage&loc=2&r=32&doct=0&rfunc=91&tj=none™32&cref=cj.
   Google Scholar
• Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, Caruana M, Velentzis LS, Bessell T, Saville M, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017 Feb 2:(2):e96–e107. doi:10.1016/S2468-2667(17)30007-5. PMID: 29253402.
   PubMed Web of Science ®Google Scholar
• Hoffman SR, Le T, Lockhart A, Sanusi A, Dal Santo L, Davis M, McKinney DA, Brown M, Poole C, Willame C, et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review. Int J Cancer. 2017 Jul 1;141(1):8–23. doi:10.1002/ijc.30623. PMID: 28124442.
   PubMed Web of Science ®Google Scholar
• Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. CMAJ. 2013 Jan 08;185(1):13–14. doi:10.1503/cmaj.121505.
   PubMed Web of Science ®Google Scholar
• Johnson HC, Lafferty EI, Eggo RM, Louie K, Soldan K, Waller J, Edmunds WJ. Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study. Lancet Public Health. 2018 Jan;3(1):e44–e51. doi:10.1016/S2468-2667(17)30238-4. PMID: 29307388.
   PubMed Web of Science ®Google Scholar
• Llanos AA, Tsui J, Rotter D, Toler L, Stroup AM. Factors associated with high-risk human papillomavirus test utilization and infection: a population-based study of uninsured and underinsured women. BMC Womens Health. 2018 Oct 3;18(1):162. doi:10.1186/s12905-018-0656-3. PMID: 30285820.
   PubMedGoogle Scholar
• Sabeena S, Bhat PV, Kamath V, Bhat SK, Nair S. Community-based prevalence of genital human papillomavirus (HPV) infection: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2017 Jan 1;18(1):145–54. doi:10.22034/APJCP.2017.18.1.145. PMID: 28240509.
   PubMedGoogle Scholar